A phase II study of paclitaxel in advanced bronchioloalveolar carcinoma ( EORTC trial 08956 ) 1

a University of Tovino, Department of Clinical and B iological Sciences, S. Luigi Hospital, Regione Gonzole 10, Orbassano (Torino) 10043, Italy b Martini Ziekenhuis, Groningen, The Netherlands c Centre Hospitalier de la Cittadelle, Liège, Belgiu m d Royal Marsden Hospital, Sutton, UK e Istituto Nazionale per la Ricerca sul Cancro, Geno va, Italy f University Hospital Na Bulovce, Charles University and Postgraduate Medical School, Prague, Czech Republic g Universitaetsklinikum-Essen, Essen, Germany h Stichting Oosterschelde Ziekenhuizen, Goes, The Ne therlands i Daniel den Hoed Cancer Center of the Erasmus MC, R otterdam, The Netherlands J EORTC Data Center, Brussels, Belgium k Vrije Universiteit Medisch Centrum, Amsterdam, The Netherlands

[1]  R. Govindan,et al.  The epidemiology of bronchioloalveolar carcinoma over the past two decades: analysis of the SEER database. , 2004, Lung cancer.

[2]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[3]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[4]  William Pao,et al.  Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  M. Kris,et al.  Clinical pattern and pathologic stage but not histologic features predict outcome for bronchioloalveolar carcinoma. , 2002, The Annals of thoracic surgery.

[6]  P. Cagle,et al.  Prognostic significance of percentage of bronchioloalveolar pattern in adenocarcinomas of the lung. , 2001, Annals of diagnostic pathology.

[7]  E. Mark,et al.  Bronchoalveolar carcinoma: clinical, radiologic, and pathologic factors and survival. , 1999, The Journal of thoracic and cardiovascular surgery.

[8]  C. Mountain,et al.  Revisions in the International System for Staging Lung Cancer. , 1997, Chest.

[9]  J. E. Barkley,et al.  Bronchioloalveolar carcinoma. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  S. Barsky,et al.  Rising incidence of bronchioloalveolar lung carcinoma and its unique clinicopathologic features , 1994, Cancer.

[11]  A. Gazdar,et al.  Interobserver variability in histopathologic subtyping and grading of pulmonary adenocarcinoma , 1993, Cancer.

[12]  E. Wynder,et al.  Relation of bronchioloalveolar carcinoma to tobacco. , 1992, BMJ.

[13]  P. Pairolero,et al.  Bronchoalveolar carcinoma: factors affecting survival. , 1991, The Annals of thoracic surgery.

[14]  F. Clayton.  Bronchioloalveolar carcinomas. Cell types, patterns of growth, and prognostic correlates , 1986, Cancer.

[15]  I. Todd,et al.  Bronchial Carcinoma , 1930, Edinburgh Medical Journal.